BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1726 related articles for article (PubMed ID: 16504015)

  • 21. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of cyclooxygenase2-prostaglandinE2 pathway on Helicobacter pylori-induced urokinase-type plasminogen activator system in the gastric cancer cells.
    Iwamoto J; Mizokami Y; Takahashi K; Matsuoka T; Matsuzaki Y
    Helicobacter; 2008 Jun; 13(3):174-82. PubMed ID: 18466392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The expression of urokinase-type plasminogen activator and its receptor in urinary transitional cell carcinoma].
    Li YJ; Zheng BZ; Zhou ZL
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Jan; 35(1):57-9. PubMed ID: 14981816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
    Mamoune A; Kassis J; Kharait S; Kloeker S; Manos E; Jones DA; Wells A
    Exp Cell Res; 2004 Sep; 299(1):91-100. PubMed ID: 15302576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aspirin inhibits highly invasive prostate cancer cells.
    Lloyd FP; Slivova V; Valachovicova T; Sliva D
    Int J Oncol; 2003 Nov; 23(5):1277-83. PubMed ID: 14532966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
    Mohanam S; Chandrasekar N; Yanamandra N; Khawar S; Mirza F; Dinh DH; Olivero WC; Rao JS
    Oncogene; 2002 Nov; 21(51):7824-30. PubMed ID: 12420219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Saposin C stimulates growth and invasion, activates p42/44 and SAPK/JNK signaling pathways of MAPK and upregulates uPA/uPAR expression in prostate cancer and stromal cells.
    Koochekpour S; Sartor O; Hiraiwa M; Lee TJ; Rayford W; Remmel N; Sandhoff K; Minokadeh A; Patten DY
    Asian J Androl; 2005 Jun; 7(2):147-58. PubMed ID: 15897971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
    Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
    Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of the uPAR-uPA system retards angiogenesis, invasion, and in vivo tumor development in pancreatic cancer cells.
    Gorantla B; Asuthkar S; Rao JS; Patel J; Gondi CS
    Mol Cancer Res; 2011 Apr; 9(4):377-89. PubMed ID: 21389187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urokinase plasminogen activator receptor promotes macrophage infiltration into the vascular wall of ApoE deficient mice.
    Gu JM; Johns A; Morser J; Dole WP; Greaves DR; Deng GG
    J Cell Physiol; 2005 Jul; 204(1):73-82. PubMed ID: 15573379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
    Zhou Q; Liang LJ; Peng BG; Zhen YY
    Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Physical association of uPAR with the alphaV integrin on the surface of human NK cells.
    Gellert GC; Goldfarb RH; Kitson RP
    Biochem Biophys Res Commun; 2004 Mar; 315(4):1025-32. PubMed ID: 14985115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.
    Henic E; Sixt M; Hansson S; Høyer-Hansen G; Casslén B
    Gynecol Oncol; 2006 Apr; 101(1):28-39. PubMed ID: 16263158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
    Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
    Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells.
    Mi Z; Guo H; Wai PY; Gao C; Kuo PC
    Carcinogenesis; 2006 Jun; 27(6):1134-45. PubMed ID: 16474180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IL-1beta increases uPA and uPA receptor expression in human gingival fibroblasts.
    Ogura N; Tobe M; Tamaki H; Nagura H; Abiko Y
    IUBMB Life; 2001 Jun; 51(6):381-5. PubMed ID: 11758807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion.
    Albo D; Berger DH; Tuszynski GP
    J Surg Res; 1998 Apr; 76(1):86-90. PubMed ID: 9695745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteomic identification of lynchpin urokinase plasminogen activator receptor protein interactions associated with epithelial cancer malignancy.
    Saldanha RG; Molloy MP; Bdeir K; Cines DB; Song X; Uitto PM; Weinreb PH; Violette SM; Baker MS
    J Proteome Res; 2007 Mar; 6(3):1016-28. PubMed ID: 17330942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction.
    Yebra M; Goretzki L; Pfeifer M; Mueller BM
    Exp Cell Res; 1999 Jul; 250(1):231-40. PubMed ID: 10388537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
    Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
    Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 87.